Company intelligence / Profile preview
Valora Therapeutics Inc.
San Diego / La Jolla, California, United Statesvaloratherapeutics.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Preclinical
01
Overview
Valora Therapeutics has raised significant seed funding to advance its proprietary AbLec™ platform, which aims to modulate glycoimmune checkpoints by targeting specific sugar molecules on cells. The company remains in preclinical development with plans to enter human studies within two or three years. No clinical results have been reported yet.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Antibody-Lectin Chimeras (AbLecs)chimeric antibodiesimmunotherapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive license from Stanford University for core technology; no major pharma partnerships disclosed yet.
Beyond the preview
Go deeper on Valora Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valora Therapeutics Inc..